Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294649" target="_blank" >RIV/00216208:11110/15:10294649 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10294649

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s10067-014-2816-7" target="_blank" >http://dx.doi.org/10.1007/s10067-014-2816-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10067-014-2816-7" target="_blank" >10.1007/s10067-014-2816-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters

Popis výsledku v původním jazyce

Rituximab (RTX) was reported effective in ANCA-associated vasculitis (AAV). We aimed to evaluate clinical efficacy of RTX in AAV along with its impact on immunological parameters. Eighteen RTX-treated AAV patients (M/F 11/7; median age 37.5; 15x PR3-ANCA, 3x MPO-ANCA; 16x relapsing/refractory, 2x first-line therapy) were enrolled. Clinical response, ANCA, total serum IgG levels and cellular immunity parameters were examined. The patients were followed up (FU) for a median of 26 months (range 3-82, 15 for a parts per thousand yen6 months). All patients achieved B cell depletion (lasting 3-24 months). No significant increase was noted in T cell or NK cell subpopulations. At 6 months, partial remission was achieved in 5/15 patients (33 %) and complete in8 (53 %). The median prednisone dose (30..10 mg/d) and ANCA levels (17.2..2.7 IU/mL) decreased (p < 0.01). RTX retreatment was used in nine (8x pre-emptive, 1x relapse). Six patients relapsed (none of the pre-emptively treated). Three pat

Název v anglickém jazyce

Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters

Popis výsledku anglicky

Rituximab (RTX) was reported effective in ANCA-associated vasculitis (AAV). We aimed to evaluate clinical efficacy of RTX in AAV along with its impact on immunological parameters. Eighteen RTX-treated AAV patients (M/F 11/7; median age 37.5; 15x PR3-ANCA, 3x MPO-ANCA; 16x relapsing/refractory, 2x first-line therapy) were enrolled. Clinical response, ANCA, total serum IgG levels and cellular immunity parameters were examined. The patients were followed up (FU) for a median of 26 months (range 3-82, 15 for a parts per thousand yen6 months). All patients achieved B cell depletion (lasting 3-24 months). No significant increase was noted in T cell or NK cell subpopulations. At 6 months, partial remission was achieved in 5/15 patients (33 %) and complete in8 (53 %). The median prednisone dose (30..10 mg/d) and ANCA levels (17.2..2.7 IU/mL) decreased (p < 0.01). RTX retreatment was used in nine (8x pre-emptive, 1x relapse). Six patients relapsed (none of the pre-emptively treated). Three pat

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Rheumatology

ISSN

0770-3198

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

107-115

Kód UT WoS článku

000347160600014

EID výsledku v databázi Scopus

2-s2.0-84925538075